An Exploratory Multiome Analysis of a BCG-Associated HSPC Signature: Trained-Immunity Marker in Blood and an Adverse Prognostic Association in Tumour

Abstract

Intravesical Bacillus Calmette--Guérin (BCG) is an established treatment for non-muscle-invasive bladder cancer (NMIBC), and recent evidence indicates that bladder BCG induces transcriptional and chromatin changes in hematopoietic stem and progenitor cells (HSPCs). However, the joint multi-omic structure of these BCG-associated changes and its potential to define transferable molecular signatures remain less well characterized. This study performed an exploratory integrative analysis of paired single-cell RNA-seq and ATAC-seq data from two NMIBC patients sampled before and after BCG treatment. Following preprocessing and barcode-level integration, 653 HSPCs were analysed using Multi-Omics Factor Analysis (MOFA+) with 2,000 HSPC-specific variable genes and 25,000 variable chromatin-accessibility peaks. Of ten latent factors, Factor~1 showed the strongest association with BCG status ($r=0.495$) and captured variation across both molecular views. RNA weights from Factor~1 were used to derive candidate gene signatures that showed partial consistency across patient-specific models. Cross-context evaluation showed associations with overall survival in TCGA-BLCA and recurrence in GSE199471, while a subset of signature genes showed consistent directional changes in monocytes following BCG vaccination in GSE184241. Together, these findings identify a candidate multi-omic axis associated with BCG exposure and suggest that its derived molecular signatures exhibit context-dependent behaviour across distinct biological and clinical settings.

Abstract: arXiv descriptive metadata (CC0). Thank you to arXiv for use of its open access interoperability. This service was not reviewed or approved by, nor does it necessarily express or reflect the policies or opinions of, arXiv.